The CCND2 antibody is a crucial tool for studying Cyclin D2. a protein encoded by the *CCND2* gene, which plays a pivotal role in regulating the cell cycle. Cyclin D2 belongs to the D-type cyclin family and functions as a regulatory subunit of cyclin-dependent kinases (CDK4/6), driving the G1-to-S phase transition by phosphorylating retinoblastoma (Rb) proteins. This process is essential for cell proliferation, differentiation, and tissue development. Dysregulation of CCND2 expression is implicated in various cancers (e.g., lymphomas, breast cancer) and developmental disorders, making it a biomarker of interest in oncology and biomedical research.
CCND2 antibodies are typically raised against specific epitopes of the Cyclin D2 protein, enabling detection and quantification in techniques like Western blotting, immunohistochemistry (IHC), and flow cytometry. These antibodies help elucidate CCND2's expression patterns, post-translational modifications, and interactions with CDKs or inhibitors (e.g., p21. p27). Researchers also use CCND2 antibodies to explore its role in diseases, such as its overexpression in certain tumors or reduced levels in conditions like primary ovarian insufficiency. Validated antibodies are critical for ensuring specificity, minimizing cross-reactivity with homologous cyclins (D1/D3), and supporting translational studies targeting cell cycle pathways for therapeutic intervention.